Our resource hub is home to a wealth of articles, stories and videos about managing and living with type 1 diabetes.
Place your order for our free information packs that support adults and children who have been recently diagnosed.
Our researchers are working on different ways to develop a cure for type 1 diabetes - from growing insulin-producing beta cells in labs to hacking the immune system.
Learn about the technologies that can deliver insulin automatically when needed. And discover the next generation of insulins that are currently being developed.
You could win a cash prize of up to £25,000 when you play the Breakthrough T1D lottery. As well as the chance to win great prizes, you’ll also help fund our research to find a cure for type 1 diabetes.
Choose from a selection of modern and traditional designs in single or twin packs to support type 1 diabetes research this Christmas. Shop online and get fast delivery.
The announcement is the biggest treatment breakthrough for type 1 diabetes since the discovery of insulin.
This World Diabetes Day, we’re inviting you to celebrate by wearing your most joyful, whimsical and downright wonderful outfits.
We provide a wealth of information and free resources to help you support and empower your patients or students.
Take our free course for schools to learn more about supporting pupils with type 1 diabetes in educational settings.
JDRF has now rebranded to Breakthrough T1D. Our name has changed, our mission has not.
Home > News & Events > News
Professor David Baker, a Breakthrough T1D-funded researcher at the University of Washington, has been awarded a Nobel Prize in Chemistry.
Our new name, Breakthrough T1D, reflects our exclusive focus on the type 1 diabetes (T1D) community. Breakthrough T1D will continue JDRF’s journey, accelerating breakthroughs in research, breakthroughs in access to treatments, and bringing the T1D community together to help everyone make their own personal breakthroughs.
A study we helped conduct, which has just been published, reveals the most important unanswered questions about type 1 diabetes, based on the priorities of adults in the United Kingdom and Ireland. This will help guide future research to focus on what matters most to people living with the condition.
When given to mice and pigs with type 1 diabetes, a new type of oral insulin developed with JDRF funding detects rising blood glucose and quickly lowers it to a safe level without causing hypos.
New research finds that ustekinumab, a drug commonly used to treat psoriasis, may help children and adolescents with type 1 diabetes keep making insulin for longer.
New international guidance detailing how to monitor and support people with early-stage type 1 diabetes (T1D) has the potential to reduce the trauma associated with being diagnosed with T1D, enable people to access the latest treatments to delay the need for insulin therapy, and reduce long-term health complications.
JDRF ambassador James Norton will read a CBeebies Bedtime Story this Diabetes Awareness Week to help young children understand type 1 and how it can be managed
The leading global type 1 diabetes charity, JDRF International (JDRF) is proud to unveil its new brand and name, Breakthrough T1D. The new name embodies its mission to cure and treat type 1 diabetes (T1D), while supporting everyone who lives with the condition.
Medtronic Diabetes have announced they are funding the biopharmaceutical company Arecor Therapeutics to develop a novel, highly concentrated, thermostable insulin, which will be specialised for use in implantable insulin pumps.
The award recognises Professor Dayan’s remarkable accomplishments in type 1 diabetes research.
Two siblings who have unique changes in a key gene have given researchers new insights that could help lead to innovative new treatments in type 1 diabetes.
JDRF and Digibete have teamed up to create Coping with Diabetes, a new interactive support tool to help children and young people with type 1 look after their mental health and wellbeing.
A new test by Randox, developed with JDRF-funded researchers at the University of Exeter, is the first in the world to use genetics to quickly identify who is at high risk of developing type 1 diabetes.
A transplant of stem cells grown into pancreatic islets has allowed a primate with type 1 to make its own insulin again.
Diabetes is the leading cause of kidney disease in the UK, so we've joined forces with Diabetes UK, and Kidney Research UK to identify the research gaps and care needs in the field.
JDRF and the Helmsley Charitable Trust have announced over £1.5 million in joint funding for five international researchers – including one UK-based researcher – to access unique data sources and unravel how type 1 diabetes develops, with the goal of preventing the condition.
We wrote to the producers of the hit BBC show after they broadcast jokes about type 1 diabetes.
Researchers have developed a new oral insulin that travels in an inactive state to the liver and is only activated by rising blood glucose levels.
Parliamentary Inquiry chaired by our Global Health Ambassador, Rt. Hon Theresa May MP and Sir George Howarth MP, highlights the risks of type 1 diabetes-related eating disorders (T1DE).
We could be one step closer to replacing the need for regular insulin injections in people living with type 1 diabetes, thanks to Breakthrough T1D UK-funded research in Australia published this week in the Nature journal.
Last night JDRF teamed up with the Royal Osteoporosis Society to host a charity carol concert at St Paul’s Cathedral. The event featured a lineup of familiar faces, including The Rt. Hon Theresa May MP and Derrick Evans MBE.
In an historic advancement in the treatment of type 1 diabetes, the National Institute for Health and Care Excellence (NICE) today approves hybrid closed loop for the majority of people living with type 1 diabetes in England and Wales.
EDENT1FI aims to develop a population screening programme for type 1, revolutionising how the condition is diagnosed and managed.
It's been an incredible year for advancements in type 1 diabetes research and treatments. We take a look at the progress we made in 2023, funded by you, our supporters.
We support the introduction of dedicated sex and gender policies in UK research, which will encourage scientists to think about sex and/or gender in their research.
The newest member of our innovative autoimmune research initiative, Connect Immune Research, is Juvenile Arthritis Research.
World-first clinical trial finds drug can suppress progression of type 1 diabetes in people newly diagnosed
The research, which was co-funded by JDRF, reveals that drugs that target the immune system offer very effective and rapid improvements in stabilising blood sugar levels, often within just three months.
The new JDRF-funded clinical trial called SOPHIST will test a drug to help people with type 1 diabetes and heart failure.
Results from a clinical trial called the PROTECT study show that teplizumab can preserve beta cell function in children and adolescents newly diagnosed with type 1 diabetes.
Children in Northern Ireland are now eligible for a trial screening programme that will identify those at high risk of developing type 1 diabetes in the future.
Thanks to JDRF supporters, we’ve been able to award a £1.3 million grant to King’s College London (KCL) and Steno Diabetes Center Copenhagen to examine how existing drugs, known as SGLT inhibitors, could delay the progression of kidney disease in people living with type 1 diabetes.
A JDRF-supported trial published in the New England Journal of Medicine and presented at the European Association for the Study of Diabetes conference has shown that hybrid closed loop technology helps pregnant women better manage their blood sugars compared to traditional insulin pumps or multiple daily injections.
A clinical trial funded by JDRF suggests that treating children with antiviral drugs when they are first diagnosed with type 1 diabetes could preserve their ability to produce some insulin.
Professor Roman Hovorka, who JDRF has funded since 2006 to develop hybrid closed loop (HCL) technology, has won this year’s EASD-Novo Nordisk Foundation Diabetes Prize for Excellence.
Don’t miss out on the latest research, inspiring stories, tech news, upcoming events, and handy information on living well with type 1. Join us now and receive it all straight to your inbox.
Our research is improving the lives of people with type 1 and making strides towards a cure. We’ll keep pushing until we make type 1 diabetes a thing of the past.
